Bourgeoning Cancer Targets

Identifying cancer genomes has provided acuity into somatically altered genes athwart tumors, transformed our understanding of biology, and helped us design therapeutic strategies. Though the action of most cancer cells remains furtive yet many features of cancer surpass their genomes. Consequently, the characterization of tumor genome does not affect the treatment of many patients. Strategies to know the circuity and function of cancer genes provide corresponding methods to explicate both non-oncogene and oncogene deficiencies. The emerging techniques specify that the therapeutic targets produced by non-oncogene deficiencies are much grander than the mutated genes. In the present review, a framework of the long-drawn-out list of cancer targets viz. synthetic lethal targets, oncogene dependence, response to DNA damage, tumor suppressor rescue, metabolic susceptibility, protein-protein interaction, cell state or master regulators, targeting immune cells, fibroblasts, etc. giving innovative prospects for clinical translation, are discussed.